PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2017, 129 (08) : 801 - 810
  • [2] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [3] PCSK9 Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
    Zhuravleva, Marina, V
    Prokofievl, Alexey B.
    Shikh, Evgenia, V
    Serebrova, Svetlana Yu
    Gorodetskaya, Galina, I
    Demchenkova, Elena Yu
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (04) : 644 - 653
  • [4] The PCSK9 revolution: Current status, controversies, and future directions
    Warden, Bruce A.
    Fazio, Sergio
    Shapiro, Michael D.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (03) : 179 - 185
  • [5] Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
    Dayoub, Elias J.
    Eberly, Lauren A.
    Nathan, Ashwin S.
    Khatana, Sameed Ahmed M.
    Adusumalli, Srinath
    Navar, Ann Marie
    Giri, Jay
    Groeneveld, Peter W.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (09):
  • [6] PCSK9 inhibitors and cardiovascular outcomes
    Steffens, Daniel
    Bramlage, Peter
    Scheeff, Celine
    Kasner, Mario
    Hassanein, Adel
    Friebel, Julian
    Rauch-Kroehnert, Ursula
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
  • [7] PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
    Marco-Benedi, Victoria
    Sanchez-Hernandez, Rosa M.
    Diaz, Jose Luis
    Jarauta, Estibaliz
    Suarez-Tembra, Manuel
    Pinto, Xavier
    Morillas, Carlos
    Plana, Nuria
    Pedro-Botet, Juan
    Civeira, Fernando
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [8] PCSK9 inhibitors in clinical practice: Novel directions and new experiences
    Rallidis, Loukianos S.
    Skoumas, Ioannis
    Liberopoulos, Evangelos N.
    Vlachopoulos, Charalambos
    Kiouri, Estela
    Koutagiar, Iosif
    Anastasiou, Georgia
    Kosmas, Nikolaos
    Elisaf, Moses S.
    Tousoulis, Dimitrios
    Iliodromitis, Efstathios
    HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (04) : 241 - 245
  • [9] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Do, Rose Q.
    Vogel, Robert A.
    Schwartz, Gregory G.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
  • [10] PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads
    Annemans, Lieven
    Stock, Jane K.
    Chapman, John
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 714 - 720
12345